1. Volume 15, Issue 6, Pages 620-630 (May 2014)
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study 
Dr Pippa G Corrie, PhD, Andrea Marshall, PhD, Prof Janet A Dunn, PhD, Prof Mark R Middleton, PhD, Paul D Nathan, PhD, Prof Martin Gore, PhD, Prof Neville Davidson, FRCP, Steve Nicholson, PhD, Charles G Kelly, FRCR, Maria Marples, PhD, Sarah J Danson, PhD, Ernest Marshall, MD, Stephen J Houston, MD, Ruth E Board, PhD, Ashita M Waterston, PhD, Jenny P Nobes, FRCR, Mark Harries, PhD, Satish Kumar, MD, Gemma Young, MPhil, Paul Lorigan, MD 
The Lancet Oncology 
Volume 15, Issue 6, Pages (May 2014)
DOI: /S (14)70110-X
Copyright © 2014 Corrie et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
HR=hazard ratio. *Patients were included in the longitudinal quality-of-life analysis if they had completed at least two questionnaires.
The Lancet Oncology  , DOI: ( /S (14)70110-X)
Copyright © 2014 Corrie et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2
Overall survival (A) and distant metastasis-free interval (B), analysis unadajusted for stratification factors
HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (14)70110-X)
Copyright © 2014 Corrie et al. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3
Disease-free interval for all patients (A), for patients with a BRAF mutation (B), and for those with BRAF wild type (C)
HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (14)70110-X)
Copyright © 2014 Corrie et al. Open Access article distributed under the terms of CC BY Terms and Conditions

5. Figure 4
Hazard ratio plot of the treatment effect by prognostic factors for disease-free interval
O–E=observed–expected events. HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (14)70110-X)
Copyright © 2014 Corrie et al. Open Access article distributed under the terms of CC BY Terms and Conditions